English-language podcasts

Art of Boring

Consumer Biotech: The Value Chain Beneath the GLP-1 Boom | EP 234

23 min

Listen through the publisher, then discuss the episode here or arrange an in-person Roundtable. Your city determines where to meet.

Roundtables are designed for groups of four, with a shared subject and room for everyone to speak. Come for discussion, with no dating expectation.

GLP-1 drugs and the peptide supply chain behind them have grown like no other drug class, reaching 44 million users within five years. Equity analyst Joshua Samuel looks past innovators Eli Lilly and Novo Nordisk to the contract manufacturers and consumables underneath them. He explains why oral GLP-1 pills can need up to 10 times more drug substance than an injection, walks through building a 39-amino-acid peptide like a LEGO set, and lays out why a silica gel supplier with about 70% global market share does not screen as a healthcare company. The conversation lands on a simple idea: growth in this market rests on several independent drivers rather than one. 0:00 - Introduction: GLP-1s Beyond the AI Trade 1:17 - Consumer Biotech: 44 Million GLP-1 Users in Five Years 2:49 - Small Molecules, Biologics, and Peptides Explained 5:01 - GLP-1 Generics, Oral Pills, and Patent Expiry 6:48 - Why Oral GLP-1 Pills Need More API 8:28 - How Peptides Are Made: The LEGO Analogy 10:56 - The Purification Bottleneck and Silica Gel 12:29 - Why Drug Approvals Lock In Suppliers 13:37 - Peptides vs. Semiconductors: Growth Drivers and Multi-Agonists 15:00 - Valuations: CDMOs vs. Consumables 19:30 - Other Healthcare Trends: Biosimilars and Small Molecule Complexity 21:53 - Outro & Subscribe GLP-1s have ramped to 44 million users within five years of Ozempic's launch, outpacing blockbuster small-molecule and biologic drugs and becoming what some now call consumer biotech. Peptide demand has moved from kilograms to tonnes. Five to seven years ago, a 100 kg API order could put a buyer in a contract manufacturer's top 10 for the year. Patent expiries and oral pills both add volume. Sandoz estimates generics could expand the market 2-7x over 5-10 years, and oral pills need 2-4x more API at Novo Nordisk and 8-10x elsewhere. Purification is the step no manufacturer can skip. Across 39 assembly steps, small yield losses compound, and once a drug is past phase two, its silica gel supplier is effectively locked in. The team owns a silica gel supplier with about 70% global share whose healthcare business is roughly 15% of sales but almost 40% of profits, and which trades like a specialty chemicals company. Beyond peptides, easier biosimilar approval is shifting work toward analytical software, and close to 70% of small molecules in development now need four to seven synthesis steps rather than two or three. Mawer employs over 250 people in Canada, U.S., and Singapore. Visit us at:

Episode information is provided by the publisher. Listening takes place on the publisher’s service.

Listen at the source ↗

Featured places to meet in Palo Alto, CA

Explore these places and arrange a conversation through ThinkMatch.

City guide for Palo Alto, CA

More from Art of Boring

Art of Boring

More Chess Pieces: Adapting Portfolio Construction to a Different Market | EP 238

20 min

Global equity portfolio manager Paul Moroz explains why the market trades differently than it did a decade ago and how the team is adapting the way it builds and manages portfolios in response. He describes a market where stocks increasingly move on sentiment, short-term trading, and a handful of data points rather than on how the underlying business is performing, and what that means for sizing positions, deploying capital, and keeping perspective when prices swing. Through it all, the conversation returns to the one question that grounds every decision: what is an investment actually worth? 0:00 Introduction: Market Structure and Outsized Price Moves 0:40 Why the AI Trade Moves Stocks on a Delta, Not on a Beat or a Miss 1:17 Creating Balance as AI Stocks Swing 4:12 Alphabet Earnings: Search Growth Near 12% Against 15% Expected 6:34 The Less Efficient Market Hypothesis 6:59 From 50 Names to Close to 90: More Chess Pieces on the Board 8:54 Is Alphabet Cheaper After the Drop, or De-Rati

Discuss this episode

Art of Boring

AI Adoption: How Investors Can Tell Whether a Company Is Keeping Up | EP 237

28 min

A one-sentence AI request might use 10 tokens, while one that needs a live search and a database lookup can use tens of thousands. Mawer Chief Technology Officer Justin Anderson explains what happens between pressing enter and getting an answer, and why that gap drives what AI costs a company. He walks through the value-over-cost equation behind AI spending, describes why Mawer built its own harness, and lays out how to tell an AI dinosaur from a rat racer or an AI native when evaluating management teams. The conversation ends on where human judgment matters: interviewing management, spotting inflection points, and keeping pace with the technology. Key Takeaways: • Every AI request is broken into tokens, and cost follows the token count. A one-sentence summary might use 10 tokens, while a request needing a live search or database lookup can use tens of thousands. • Justin splits the return on AI into value, owned by business teams, and cost, owned by technology. Mawer built a harness t

Discuss this episode

Art of Boring

AI Build-Out: What We Know, What We Don't, and What's in the Stock | EP 236

19 min

Mawer equity analyst Irena Petkovic separates what the team knows about the AI build-out from what it doesn't, after several volatile weeks for AI stocks and hyperscaler earnings. She covers the latest hyperscaler results, where growth is now limited by how fast new data centers can be built, and what Anthropic's S-1 filing says about how much room enterprise AI adoption has left. On the unknowns, she lays out the U.S. midterm results, the financing of the data center build-out, and how AI agents, software that uses the internet on a person's behalf without clicking on ads, could change which online businesses capture value. She then explains how the team asks what's in the stock, meaning the assumptions a share price already contains, and what that meant for Alphabet. Key Takeaways: Hyperscaler AI results accelerated again, and supply is the constraint. AWS posted a sixth straight quarter of revenue acceleration, Google Cloud doubled year over year, and all four hyperscalers said grow

Discuss this episode

Community Poll

Cities should actively seek views from residents who do not attend public meetings.

Share your view, then see how readers voted. No sign-in required. This poll is shared across stories.

Do you agree or disagree?

Choose one answer

Common Quandary

A Common Quandary to discuss

Another conversation to explore, separate from this news story.

A stranger takes an emotional call in the quiet car. Do you shush them?

On a crowded train's designated quiet car, a passenger answers a call and begins discussing an apparent family emergency. They are speaking softly but continuously, and everyone nearby is listening despite trying not to.

Do public rules make room for private emergencies?

Explore this quandary